Adjuvant Immunotherapy Improves Survival in Melanoma

Source: cancernetwork, June 2020

Adjuvant immunotherapy induced improved survival compared with those who did not in patients with stage 3 melanoma, according to data from a large real-world database presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting II.

Justin Moyers, MD, fellow at Loma Linda University in California, and colleagues aimed to determine the percentage of patients receiving immunotherapy after surgery in the real-world setting, using data from the National Cancer Database (NCDB), a joint project of the Commission on Cancer (CoC) of the American College of Surgeons and the American Cancer Society.

The researchers analyzed treatment data from melanoma cases diagnosed in 2015 and 2016, and survival data from cases diagnosed in 2015. All patients had stage 3 melanoma that was surgically removed.

READ THE ORIGINAL FULL ARTICLE